US equities
|
NVDA
$221.30
▼-3.16%
MU
$914.13
▼-4.10%
AAPL
$342.96
▲+0.50%
AMD
$570.82
▼-5.73%
META
$737.54
▼-3.27%
MSFT
$533.69
▼-1.80%
TSLA
$367.16
▼-2.15%
SPCX
$152.16
▼-2.80%
NVDA
$221.30
▼-3.16%
MU
$914.13
▼-4.10%
AAPL
$342.96
▲+0.50%
AMD
$570.82
▼-5.73%
META
$737.54
▼-3.27%
MSFT
$533.69
▼-1.80%
TSLA
$367.16
▼-2.15%
SPCX
$152.16
▼-2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Forma Therapeutics Holdings, Inc. - Common Stock
(NQ:
FMTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 13, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Forma Therapeutics Holdings, Inc. - Common Stock
< Previous
1
2
3
Next >
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
October 07, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
↗
October 03, 2021
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...
Via
Benzinga
Forma Therapeutics to Participate in Upcoming Investor Conferences
September 17, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
↗
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
↗
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
↗
August 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...
Via
Benzinga
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Earnings Scheduled For August 13, 2021
↗
August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd...
Via
Benzinga
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
August 06, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021
↗
August 02, 2021
Upgrades For Consolidated Communications Holdings Inc (NASDAQ:
Via
Benzinga
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
June 14, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
64 Biggest Movers From Friday
↗
June 14, 2021
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained...
Via
Benzinga
Topics
Initial Public Offering
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
↗
June 11, 2021
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease. Data were...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
June 11, 2021
Friday morning, 5 companies reached new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Vertex Pharmaceuticals (NASDAQ:VRTX...
Via
Benzinga
46 Stocks Moving In Friday's Mid-Day Session
↗
June 11, 2021
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67...
Via
Benzinga
Topics
Initial Public Offering
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 11, 2021
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,...
Via
Benzinga
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
June 11, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Forma Therapeutics' Olutasidenib Achieves 33% Remission Rate In Acute Myeloid Leukemia Patients
↗
May 20, 2021
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced interim data from its Phase 2 trial of olutasidenib in relapsed/refractory acute myeloid leukemia (R/R AML...
Via
Benzinga
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
May 20, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
↗
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Forma Therapeutics to Participate in Upcoming Investor Conferences
May 17, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
↗
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
↗
May 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Earnings Scheduled For May 14, 2021
↗
May 14, 2021
Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report...
Via
Benzinga
Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
May 06, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
↗
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
< Previous
1
2
3
Next >
